 Yong-Chen Lu
Concepts (222)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antigens, Neoplasm | 13 | 2022 | 151 | 4.360 |
Why?
| | Receptors, Antigen, T-Cell | 10 | 2022 | 50 | 3.200 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 17 | 2022 | 76 | 3.110 |
Why?
| | Immunotherapy, Adoptive | 8 | 2019 | 154 | 2.620 |
Why?
| | Immunotherapy | 6 | 2024 | 238 | 2.580 |
Why?
| | T-Lymphocytes | 9 | 2022 | 338 | 2.570 |
Why?
| | Neoplasms | 10 | 2024 | 1233 | 2.520 |
Why?
| | CD4-Positive T-Lymphocytes | 5 | 2024 | 163 | 1.680 |
Why?
| | Cancer Vaccines | 4 | 2021 | 78 | 1.460 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2021 | 169 | 1.300 |
Why?
| | Mutation | 13 | 2019 | 1293 | 0.990 |
Why?
| | Single-Cell Analysis | 3 | 2022 | 55 | 0.810 |
Why?
| | CD8-Positive T-Lymphocytes | 8 | 2024 | 115 | 0.730 |
Why?
| | Immune System | 1 | 2020 | 44 | 0.710 |
Why?
| | Alcohol Oxidoreductases | 1 | 2019 | 13 | 0.680 |
Why?
| | HLA-DP beta-Chains | 2 | 2017 | 2 | 0.640 |
Why?
| | Neoplasm Proteins | 2 | 2017 | 323 | 0.610 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2019 | 157 | 0.590 |
Why?
| | Genetic Therapy | 2 | 2017 | 114 | 0.590 |
Why?
| | DNA-Binding Proteins | 2 | 2019 | 436 | 0.560 |
Why?
| | Melanoma | 3 | 2016 | 284 | 0.540 |
Why?
| | Animals | 16 | 2024 | 13150 | 0.510 |
Why?
| | Humans | 35 | 2024 | 49827 | 0.490 |
Why?
| | Immunodominant Epitopes | 2 | 2015 | 8 | 0.480 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 4 | 2019 | 66 | 0.480 |
Why?
| | Signal Transduction | 7 | 2024 | 1617 | 0.480 |
Why?
| | Protein Phosphatase 1 | 1 | 2013 | 7 | 0.450 |
Why?
| | Cytokines | 4 | 2019 | 612 | 0.450 |
Why?
| | Phosphoprotein Phosphatases | 1 | 2013 | 17 | 0.440 |
Why?
| | Osteoarthritis | 2 | 2024 | 62 | 0.440 |
Why?
| | Lymphocyte Activation | 5 | 2021 | 172 | 0.440 |
Why?
| | Proto-Oncogene Proteins c-rel | 2 | 2010 | 5 | 0.430 |
Why?
| | Antibodies, Monoclonal | 1 | 2016 | 458 | 0.410 |
Why?
| | Colorectal Neoplasms | 3 | 2019 | 234 | 0.380 |
Why?
| | Neoplasm Metastasis | 3 | 2022 | 231 | 0.370 |
Why?
| | CCAAT-Enhancer-Binding Protein-beta | 1 | 2009 | 4 | 0.340 |
Why?
| | Toll-Like Receptors | 1 | 2009 | 27 | 0.340 |
Why?
| | Transcriptome | 2 | 2022 | 313 | 0.330 |
Why?
| | CCAAT-Enhancer-Binding Protein-delta | 1 | 2009 | 22 | 0.330 |
Why?
| | Lipopolysaccharides | 2 | 2022 | 191 | 0.330 |
Why?
| | Glioblastoma | 2 | 2021 | 91 | 0.320 |
Why?
| | Toll-Like Receptor 4 | 1 | 2008 | 48 | 0.300 |
Why?
| | Adoptive Transfer | 3 | 2018 | 39 | 0.270 |
Why?
| | Cells, Cultured | 5 | 2021 | 1571 | 0.260 |
Why?
| | Gene Expression Profiling | 2 | 2021 | 1031 | 0.260 |
Why?
| | Autoantigens | 2 | 2015 | 58 | 0.250 |
Why?
| | Bioprinting | 1 | 2024 | 1 | 0.240 |
Why?
| | Nanofibers | 1 | 2024 | 7 | 0.240 |
Why?
| | Skin, Artificial | 1 | 2024 | 10 | 0.240 |
Why?
| | Humerus | 1 | 2024 | 18 | 0.240 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2016 | 85 | 0.230 |
Why?
| | Gene Library | 2 | 2014 | 44 | 0.230 |
Why?
| | Receptors, Estrogen | 1 | 2024 | 130 | 0.220 |
Why?
| | Adipocytes | 1 | 2024 | 121 | 0.220 |
Why?
| | beta Catenin | 1 | 2024 | 102 | 0.220 |
Why?
| | Leptin | 1 | 2024 | 140 | 0.220 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2022 | 202 | 0.210 |
Why?
| | Thyroid Neoplasms | 1 | 2024 | 109 | 0.210 |
Why?
| | Nephritis | 1 | 2022 | 22 | 0.210 |
Why?
| | Clone Cells | 2 | 2019 | 74 | 0.210 |
Why?
| | Receptors, Immunologic | 1 | 2022 | 37 | 0.210 |
Why?
| | Bone Marrow | 1 | 2024 | 362 | 0.200 |
Why?
| | Alleles | 2 | 2014 | 251 | 0.200 |
Why?
| | Bone Neoplasms | 1 | 2024 | 179 | 0.200 |
Why?
| | Ureteral Obstruction | 1 | 2022 | 60 | 0.200 |
Why?
| | HLA-A Antigens | 2 | 2019 | 10 | 0.200 |
Why?
| | Osteogenesis | 1 | 2024 | 351 | 0.190 |
Why?
| | Human papillomavirus 16 | 1 | 2021 | 44 | 0.190 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2014 | 193 | 0.190 |
Why?
| | T-Cell Antigen Receptor Specificity | 2 | 2017 | 4 | 0.190 |
Why?
| | Membrane Glycoproteins | 1 | 2022 | 240 | 0.190 |
Why?
| | Middle Aged | 8 | 2019 | 11997 | 0.190 |
Why?
| | Papillomavirus Vaccines | 1 | 2021 | 61 | 0.180 |
Why?
| | Interleukin-2 | 2 | 2017 | 72 | 0.170 |
Why?
| | Smad5 Protein | 1 | 2019 | 1 | 0.170 |
Why?
| | Mucin-4 | 1 | 2019 | 1 | 0.170 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2022 | 168 | 0.170 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2021 | 274 | 0.160 |
Why?
| | NF-kappa B | 3 | 2024 | 314 | 0.160 |
Why?
| | Cell Differentiation | 1 | 2021 | 653 | 0.160 |
Why?
| | Mice | 7 | 2024 | 5720 | 0.160 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 467 | 0.150 |
Why?
| | Epitopes, T-Lymphocyte | 2 | 2014 | 24 | 0.150 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2022 | 553 | 0.150 |
Why?
| | Administration, Intravenous | 1 | 2017 | 68 | 0.150 |
Why?
| | Male | 7 | 2024 | 25093 | 0.150 |
Why?
| | Aged | 3 | 2024 | 9272 | 0.150 |
Why?
| | Colonic Neoplasms | 1 | 2019 | 162 | 0.140 |
Why?
| | Membrane Proteins | 1 | 2019 | 342 | 0.140 |
Why?
| | Female | 12 | 2024 | 26329 | 0.140 |
Why?
| | Flow Cytometry | 3 | 2016 | 470 | 0.140 |
Why?
| | Exome | 2 | 2014 | 46 | 0.140 |
Why?
| | CTLA-4 Antigen | 1 | 2016 | 25 | 0.140 |
Why?
| | Cell Line, Tumor | 2 | 2017 | 1402 | 0.140 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2016 | 42 | 0.130 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2016 | 38 | 0.130 |
Why?
| | Gene Expression Regulation | 2 | 2019 | 979 | 0.130 |
Why?
| | Transcription Factors | 1 | 2019 | 563 | 0.130 |
Why?
| | Transplantation, Autologous | 1 | 2017 | 456 | 0.130 |
Why?
| | Protein Binding | 2 | 2014 | 660 | 0.130 |
Why?
| | Adult | 7 | 2021 | 13160 | 0.130 |
Why?
| | Neutrophils | 2 | 2014 | 137 | 0.130 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2015 | 44 | 0.130 |
Why?
| | Treatment Outcome | 4 | 2021 | 5138 | 0.130 |
Why?
| | Time Factors | 2 | 2021 | 2912 | 0.130 |
Why?
| | Respiratory Burst | 1 | 2014 | 5 | 0.120 |
Why?
| | Hepatitis B e Antigens | 1 | 2014 | 4 | 0.120 |
Why?
| | Histocompatibility Antigens | 1 | 2014 | 6 | 0.120 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2014 | 13 | 0.120 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2019 | 829 | 0.120 |
Why?
| | Epitope Mapping | 1 | 2014 | 6 | 0.120 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2014 | 16 | 0.120 |
Why?
| | Cholangiocarcinoma | 1 | 2014 | 27 | 0.120 |
Why?
| | Bile Duct Neoplasms | 1 | 2014 | 30 | 0.120 |
Why?
| | Th1 Cells | 1 | 2014 | 51 | 0.120 |
Why?
| | Monocytes | 1 | 2014 | 132 | 0.110 |
Why?
| | Peptides | 1 | 2014 | 222 | 0.110 |
Why?
| | Gene Knockdown Techniques | 1 | 2013 | 106 | 0.110 |
Why?
| | Amino Acid Sequence | 1 | 2014 | 587 | 0.110 |
Why?
| | Genes, T-Cell Receptor | 2 | 2022 | 5 | 0.100 |
Why?
| | TNF Receptor-Associated Factor 2 | 1 | 2011 | 4 | 0.100 |
Why?
| | Base Sequence | 1 | 2013 | 650 | 0.100 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 595 | 0.100 |
Why?
| | Autoimmunity | 1 | 2011 | 35 | 0.100 |
Why?
| | Molecular Sequence Data | 1 | 2013 | 797 | 0.100 |
Why?
| | Forkhead Transcription Factors | 1 | 2012 | 112 | 0.100 |
Why?
| | Cell Line | 1 | 2014 | 1002 | 0.100 |
Why?
| | Disease Progression | 1 | 2014 | 822 | 0.100 |
Why?
| | Severe Combined Immunodeficiency | 1 | 2010 | 12 | 0.090 |
Why?
| | Lung Neoplasms | 1 | 2016 | 605 | 0.090 |
Why?
| | Clinical Trials as Topic | 1 | 2013 | 460 | 0.090 |
Why?
| | Clonal Anergy | 1 | 2010 | 13 | 0.090 |
Why?
| | Gene Rearrangement | 1 | 2010 | 74 | 0.090 |
Why?
| | Mice, Knockout | 3 | 2024 | 841 | 0.090 |
Why?
| | Protein Kinase C | 1 | 2010 | 71 | 0.090 |
Why?
| | Dendritic Cells | 2 | 2022 | 132 | 0.090 |
Why?
| | Remission Induction | 2 | 2021 | 207 | 0.090 |
Why?
| | Isoenzymes | 1 | 2010 | 168 | 0.090 |
Why?
| | Interleukin-1 Receptor-Associated Kinases | 1 | 2009 | 11 | 0.090 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2009 | 33 | 0.080 |
Why?
| | Nuclear Proteins | 1 | 2010 | 243 | 0.080 |
Why?
| | Breast Neoplasms | 1 | 2018 | 1169 | 0.080 |
Why?
| | Antineoplastic Agents | 1 | 2017 | 1172 | 0.080 |
Why?
| | Chromosome Aberrations | 1 | 2010 | 298 | 0.080 |
Why?
| | Transcriptional Activation | 1 | 2009 | 122 | 0.080 |
Why?
| | Inflammation Mediators | 1 | 2009 | 112 | 0.080 |
Why?
| | Antigen Presentation | 2 | 2019 | 25 | 0.080 |
Why?
| | Cell Separation | 2 | 2019 | 88 | 0.070 |
Why?
| | Complement C3a | 1 | 2007 | 3 | 0.070 |
Why?
| | Complement C5a | 1 | 2007 | 4 | 0.070 |
Why?
| | Macrophages | 1 | 2009 | 364 | 0.070 |
Why?
| | Fibroblasts | 2 | 2024 | 343 | 0.070 |
Why?
| | Obesity | 2 | 2024 | 1113 | 0.060 |
Why?
| | Lymphocyte Count | 2 | 2016 | 21 | 0.060 |
Why?
| | Gelatin | 1 | 2024 | 25 | 0.060 |
Why?
| | Hydrogels | 1 | 2024 | 13 | 0.060 |
Why?
| | Hyaluronic Acid | 1 | 2024 | 34 | 0.060 |
Why?
| | Tissue Scaffolds | 1 | 2024 | 32 | 0.060 |
Why?
| | Iodine Radioisotopes | 1 | 2024 | 35 | 0.060 |
Why?
| | Hedgehog Proteins | 1 | 2024 | 33 | 0.060 |
Why?
| | Keratinocytes | 1 | 2024 | 89 | 0.060 |
Why?
| | Estrogen Receptor alpha | 1 | 2024 | 89 | 0.060 |
Why?
| | Tissue Engineering | 1 | 2024 | 63 | 0.060 |
Why?
| | Mice, Inbred C57BL | 2 | 2024 | 1806 | 0.060 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2024 | 56 | 0.060 |
Why?
| | Bone Marrow Cells | 1 | 2024 | 192 | 0.060 |
Why?
| | Wnt Signaling Pathway | 1 | 2024 | 92 | 0.050 |
Why?
| | Transforming Growth Factor beta | 1 | 2024 | 144 | 0.050 |
Why?
| | Swine | 1 | 2024 | 391 | 0.050 |
Why?
| | Lipid Metabolism | 1 | 2023 | 175 | 0.050 |
Why?
| | Th17 Cells | 1 | 2022 | 26 | 0.050 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2021 | 25 | 0.050 |
Why?
| | Neoplasm Grading | 1 | 2021 | 123 | 0.050 |
Why?
| | Gene Regulatory Networks | 1 | 2022 | 107 | 0.050 |
Why?
| | Pain | 1 | 2024 | 380 | 0.050 |
Why?
| | Arginine | 1 | 2022 | 179 | 0.050 |
Why?
| | Nitric Oxide | 1 | 2022 | 253 | 0.040 |
Why?
| | Host-Pathogen Interactions | 1 | 2021 | 129 | 0.040 |
Why?
| | Blotting, Western | 2 | 2011 | 602 | 0.040 |
Why?
| | Transduction, Genetic | 1 | 2019 | 45 | 0.040 |
Why?
| | Immunologic Memory | 1 | 2019 | 30 | 0.040 |
Why?
| | Lung | 2 | 2016 | 480 | 0.040 |
Why?
| | Transplantation Conditioning | 1 | 2019 | 83 | 0.040 |
Why?
| | Coculture Techniques | 1 | 2019 | 146 | 0.040 |
Why?
| | Phenotype | 2 | 2012 | 727 | 0.040 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2019 | 73 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 119 | 0.040 |
Why?
| | Lymphatic Metastasis | 1 | 2019 | 230 | 0.040 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2018 | 114 | 0.040 |
Why?
| | HLA-DRB1 Chains | 1 | 2017 | 4 | 0.040 |
Why?
| | Cell Proliferation | 1 | 2021 | 1007 | 0.040 |
Why?
| | Antigen-Presenting Cells | 1 | 2017 | 26 | 0.040 |
Why?
| | Pilot Projects | 1 | 2019 | 699 | 0.040 |
Why?
| | Cross Reactions | 1 | 2016 | 41 | 0.030 |
Why?
| | HLA-C Antigens | 1 | 2015 | 4 | 0.030 |
Why?
| | ras Proteins | 1 | 2015 | 64 | 0.030 |
Why?
| | Inflammation | 2 | 2011 | 604 | 0.030 |
Why?
| | Risk Factors | 1 | 2023 | 3619 | 0.030 |
Why?
| | Proto-Oncogene Proteins | 1 | 2015 | 149 | 0.030 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2014 | 43 | 0.030 |
Why?
| | Chemokines | 1 | 2014 | 77 | 0.030 |
Why?
| | Vaccination | 1 | 2016 | 268 | 0.030 |
Why?
| | Receptor, erbB-2 | 1 | 2014 | 73 | 0.030 |
Why?
| | B-Lymphocytes | 1 | 2014 | 170 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2014 | 486 | 0.030 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2012 | 13 | 0.030 |
Why?
| | Whole-Body Irradiation | 1 | 2012 | 131 | 0.020 |
Why?
| | Spectral Karyotyping | 1 | 2010 | 6 | 0.020 |
Why?
| | Endonucleases | 1 | 2010 | 15 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 455 | 0.020 |
Why?
| | Lymphoma | 1 | 2010 | 65 | 0.020 |
Why?
| | Survival Analysis | 1 | 2010 | 659 | 0.020 |
Why?
| | Apoptosis | 1 | 2014 | 1100 | 0.020 |
Why?
| | DNA Damage | 1 | 2010 | 301 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2010 | 555 | 0.020 |
Why?
| | Receptors, Chemokine | 1 | 2007 | 12 | 0.020 |
Why?
| | Receptor, Anaphylatoxin C5a | 1 | 2007 | 6 | 0.020 |
Why?
| | Complement Activation | 1 | 2007 | 42 | 0.020 |
Why?
| | Cattle | 1 | 2007 | 210 | 0.020 |
Why?
| | Actins | 1 | 2007 | 118 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2010 | 1451 | 0.020 |
Why?
| | Hematopoietic Stem Cells | 1 | 2007 | 184 | 0.020 |
Why?
|
|
Lu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|